Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease)

Seminars in Liver Disease

Volumn 22, Issue 1, 2002, Pages 27-41

  DeLeve, Laurie D ^a   Shulman, Howard M ^a   McDonald, George B ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Sinusoidal obstruction; Toxic liver injury; Veno occlusive disease

Indexed keywords

ACETYLCYSTEINE; ACTIVATED PROTEIN C; ALPHA TOCOPHEROL; ANTITHROMBIN III; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEFIBROTIDE; GLUTAMINE; HEPARIN; NITRATE; PENTOXIFYLLINE; PREDNISONE; PROSTAGLANDIN E1; TISSUE PLASMINOGEN ACTIVATOR; URSODEOXYCHOLIC ACID;

ANTICOAGULATION; BLOOD CLOT LYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ECHOGRAPHY; HUMAN; INCIDENCE; LIVER BIOPSY; LIVER BLOOD FLOW; LIVER FIBROSIS; LIVER INJURY; LIVER SINUSOID; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PORTOSYSTEMIC ANASTOMOSIS; PRESSURE GRADIENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WHOLE BODY RADIATION;

EID: 0036125693     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-23204     Document Type: Review

References (189)

1. Senecio disease, or cirrhosis of the liver due to senecio poisoning
2. Senecio poisoning exhibiting as Chiari's syndrome: A report on twelve cases
3. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica
4. Characterization of a reproducible rat model of hepatic veno-occlusive disease
5. Venocclusive disease of the liver after marrow transplantation: Histologic correlates of clinical signs and symptoms
6. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan
7. An epidemic of veno-occlusive disease of the liver in Afghanistan. Pathologic features
8. Favourable outcome of hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine, treated by portacaval shunt. Report of a case and review of the literature
9. Azathioprine and hepatic venocclusive disease in renal transplant patients
10. Hepatic venocclusive disease associated with renal transplantation and azathioprine therapy
11. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: Light microscopy and ultrastructural observations
12. Veno-occlusive hepatic disease of the liver in renal transplantation: Is azathioprine the cause?
13. Azathioprine hepatotoxicity after liver transplantation
14. Vascular hepatotoxicity related to heroin addiction
15. Lack of hepatocyte involvement in the genesis of the sinusoidal dilatation related to heroin addiction: A morphometric study
16. Ultrastructural lesions of the liver in human peliosis. A report of 12 cases
17. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic veno-occlusive disease
18. Glutathione defense in non-parenchymal cells
19. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
20. Hepatic sinusoidal obstruction following Gemtuzumab ozogamicin (Mylotarg)
21. Hepatotoxicity of chemotherapy
22. Venoocclusive disease of the liver in right-sided Wilms' tumours
23. Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients
24. Hepatic toxicity resulting from cancer treatment
25. Total body irradiation and Budd-Chiari syndrome
26. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation
27. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia
28. Venocclusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
29. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors
30. Venocclusive disease of the liver after allogeneic bone marrow transplantation in man
31. Veno-occlusive disease of the liver following bone marrow transplantation
32. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European group for blood and marrow transplantation
33. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: Incidence, onset time and risk factors
34. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
35. Venocclusive disease of the liver and cyclophosphamide pharmacokinetics: A prospective study in marrow transplant patients
36. Hepatitis C virus infection after bone marrow transplantation: A cohort study with 10 year follow-up
37. Norethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation
38. Venocclusive disease of the liver after busulfan, melphalan, and thioTEPA conditioning therapy: Incidence, risk factors, and outcome
39. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation
40. Hepatobiliary complications of hematopoietic stem cell transplantation
41. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation
42. Severe hepatocellular injury after hematopoietic cell transplant: Incidence and etiology in 2136 consecutive patients
43. Von Willebrand factor, angiotensin converting enzyme and endothelial cell damage in veno-occlusive disease and bone marrow transplantation
44. Increased serum levels of tumor necrosis factor-a precede major complications of bone marrow transplantation
45. Transforming growth factor βas a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
46. Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver
47. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen
48. N-terminal peptide of type III procollagen: A marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin
49. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation
50. Transforming growth factor-beta plasma concentrations in patients with leukemia and lymphoma receiving chemoradiotherapy and marrow transplantation
51. Plasma levels of the propeptide of type III collagen predict the severity of venocclusive disease of the liver
52. Serum procollagen type III is an early and sensitive marker for venocclusive disease of the liver in children undergoing bone marrow transplantation
53. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation
54. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation
55. Serum levels of cytokines after bone marrow transplantation: Increased IL-8 levels during severe veno-occlusive disease of the liver
56. Liver venocclusive disease after bone marrow transplantation. Changes in coagulation parameters and endothelial markers
57. Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver
58. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy
59. Venocclusive disease of the liver: Prospective study of US evaluation
60. Veno-occlusive liver disease after bone marrow transplantation: Findings at duplex sonography
61. Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: Value of gray-scale and Doppler US in 100 patients
62. Hepatic outflow obstruction and liver failure due to leukemic cell infiltration in chronic lymphocytic leukemia
63. Doppler sonography: A noninvasive method for evaluation of hepatic veno-occlusive disease
64. Diagnosis of veno-occlusive disease of the liver by color-coded Doppler sonography
65. Sonographic diagnosis and hemodynamic correlation in veno-occlusive disease of the liver
66. Acute portal vein thrombosis after autologous stem cell transplantation
67. Portal vein thrombosis after hematopoietic cell transplantation: Frequency, treatment, and outcome
68. Hepatic veno-occlusive disease in children undergoing bone-marrow transplantation: Usefulness of sonographic findings
69. Transjugular liver biopsy in bone marrow transplantation
70. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients
71. The risk of bleeding after percutaneous liver biopsy: Relation to platelet count
72. Jaundice due to bacterial infection
73. Nonbacterial thrombotic endocarditis clinically mimicking veno-occlusive disease of the liver complicating autologous bone marrow transplantation
74. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation
75. The syndrome of hepatic venocclusive disease after marrow transplantation
76. Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients
77. Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients
78. Venocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation
79. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients
80. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules
81. Veno-occlusive disease of the liver following bone marrow transplantation: A clinical-pathological study of autopsy cases
82. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation
83. Cellular target of cyclophosphamide toxicity in the murine liver-role of glutathione and site of metabolic activation
84. Dacarbazine toxicity in murine liver cells: A model of hepatic endothelial injury and glutathione defense
85. Embolization by sinusoidal lining cells causes the congestion of hepatic venocclusive disease
86. Identification of two distinct mechanisms of busulfan toxicity in isolated murine hepatocytes
87. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat
88. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide
89. Prevention of hepatic venocclusive disease in the rat by inhibition of matrix metalloproteinases
90. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis
91. Myocardial matrix metalloproteinase(s): Localization and activation
92. Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells
93. Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions
94. Decrease in hepatic nitric oxide production contributes to hepatic veno-occlusive disease (HVOD)
95. Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells
96. Veno-occlusive disease of the liver after bone marrow transplantation: Is hypercoagulability really part of the problem?
97. Acute veno-occlusive disease of the liver. Fine structure in Jamaican children
98. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with TBI-containing regimens
99. Hepatic veno-occlusive disease
100. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients
101. Hepatotoxicity of cyclophosphamide in man: Pharmacokinetic analysis
102. Studies of the binding of [3H-chloroethyl]-cyclophosphamide and 14[C-4]-cyclosphosphamide to hepatic microsomes and native calf thymus DNA
103. Busulfan dose adjustment decreases the risk of hepatic veno-occlusive disease in patients undergoing bone marrow transplantation
104. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
105. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation for advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels
106. Association of busulfan area under the curve with veno-occlusive disease following BMT
107. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
108. Busulfan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted?
109. Marrow transplantation for chronic myeloid leukemia - The influence of plasma busulfan levels on the outcome of transplantation
110. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia
111. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes
112. Risk factors of hepatic venocclusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children
113. The role of busulfan in bone marrow transplantation
114. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v.BuCy)
115. Pathogenesis of veno-occlusive liver disease after radiation
116. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies
117. Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients
118. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
119. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma
120. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and Factor VIII for development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: A prospective study
121. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia
122. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation
123. Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)?
124. Results of a phase I trial of antithrombin III as prophylaxis in bone marrow transplant patients at risk for venocclusive disease
125. Venocclusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator
126. Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation
127. Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation
128. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients
129. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)
130. Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)
131. The prothrombin gene variant G20210A but not Factor V Leiden may be associated with veno-occlusive disease following BMT
132. No association between activated protein C (APC) resistance and hepatic veno-occlusive disease (VOD) following stem cell transplantation
133. Circulating markers of hepatic fibrosis predict evolution of venocclusive disease after marrow transplantation
134. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
135. Rapid analysis of tumor necrosis factor-alpha mRNA expression during venocclusive disease of the liver after allogeneic bone marrow transplantation
136. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation
137. Pathogenesis of venocclusive disease of the liver: Role of cytokines, NO, endothelin-1, and fibrosis
138. Plasma levels of endothelin-1 and nitrate in patients with venocclusive disease of the liver after hematopoietic cell transplantation
139. Marked enzymuria following bone marrow transplantation: A correlate of veno-occlusive disease-induced "hepatorenal syndrome"
140. Marrow transplantation for patients with thalassemia: Results in class 3 patients
141. Bone marrow transplantation in patients with thalassemia
142. Aspects concerning busulfan pharmacokinetics and bioavailability
143. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels
144. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation
145. Norethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation
146. Hepatic venocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas
147. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation
148. A pilot study of continuous infusion heparin for the prevention of hepatic venocclusive disease after bone marrow transplantation
149. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial
150. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation
151. Prophylactic heparin does not prevent liver venocclusive disease following autologous bone marrow transplantation
152. Prevention of veno-occlusive disease of the liver after bone marrow transplantation: Heparin or no heparin?
153. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients
154. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial
155. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation
156. Ursodiol for the prevention of hepatic complications in allogeneic stem cell transplantation
157. 1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation
158. 1 for the prevention of hepatic venocclusive disease after bone marrow transplantation
159. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation
160. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective randomized trial
161. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines
162. Recombinant human tissue plasminogen activator for the treatment of established severe hepatic venocclusive disease of the liver after bone marrow transplantation
163. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation
164. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation
165. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders
166. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in efficacy without significant toxicity in a high risk population
167. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study
168. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation
169. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer
170. 1
171. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?
172. Application of nitric oxide for a case of veno-occlusive disease after peripheral blood stem cell transplantation
173. Use of vitamin E and glutamine in the successful treatment of severe veno-occlusive disease following bone marrow transplantation
174. Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease
175. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation
176. Transjugular intrahepatic portosystemic shunts (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation
177. Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation - Role of transjugular intrahepatic portosystemic shunt (TIPS)
178. Expanding the use of transjugular intrahepatic portosystemic shunts for veno-occlusive disease
179. Acute respiratory distress syndrome precipitated by transjugular intrahepatic porto-systemic shunting for severe hepatic veno-occlusive disease. Is it due to pulmonary leucostasis?
180. Successful treatment of hepatic venocclusive disease in a bone marrow transplant patient with side-to-side portacaval shunt
181. Effective early treatment of hepatic venocclusive disease with a central splenorenal shunt in an infant
182. Successful treatment of hepatic venocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation
183. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant
184. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation
185. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation - Clinical and immunological considerations
186. Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation
187. Related donor liver transplant for veno-occlusive disease following T-depleted unrelated donor bone marrow transplantation
188. Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver